Mielodiszplasztikus szindróma (MDS): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 6
• IDH 12
• FLT3 6
• BCL-2 4
• CD19 5
• CD33 3
• RUNX1 0
• CD123 3
• JAK 3
• PARP 0
• TIM-3 0
• ABL1 0
• KMT2A 1
• CD47 0
• NPM1 2
• PD-1 1
• IL-1 2
• NLRP3 1
• ERK 0
• EZH2 0
• NRAS 0
• RAS 0
• SGLT2 1
• AKT 0
• CD20 1
• CD38 2
• CSF1R 2
• GLP-1 0
• IL-6 1
• PD-L1 0
• PI3K 1
• STING 1
• ALK 0
• AMPK 0
• AR 0
• ATM 0
• BCMA 1
• BRAF 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CCR5 0
• CD22 1
• CD40 0
• COX-2 0
• CTNNB1 0
• GPRC5D 1
• GPX4 0
• HIF-1 0
• IL-15 1
• IL-17 0
• KIT 0
• KRAS 0
• MAPK 0
• MYC 0
• PRMT5 0
• RB1 0
• STAT3 0

687 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients

  Syntrix Biosystems, Inc.· Auburn, Egyesült Államok· 406 500 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · DP2

  Single-molecule, Single-cell profiling of chromatin protein-protein interactions.

  Van Andel Research Institute· Grand Rapids, Egyesült Államok· 912 000 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NIDDK · R01

  Role of IL-1 beta signaling in stress erythropoiesis

  Pennsylvania State University, the· University Park, Egyesült Államok· 641 869 USD awarded in fiscal year 2026· until 2030. máj.

• NIH NHLBI · R01

  Mechanisms underlying germline predisposition to clonal hematopoiesis

  Albert Einstein College of Medicine· Bronx, Egyesült Államok· 693 151 USD awarded in fiscal year 2026· until 2031. máj.

• NIH NHGRI · R01

  A single-cell multiomics platform for studying genome structure and function

  University of Washington· Seattle, Egyesült Államok· 796 114 USD awarded in fiscal year 2026· until 2030. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Towards novel approaches for Myelodysplastic Syndromes diagnosis to Strengthen Research Human Capital with Cross-Sectoral and Interdisciplinary Staff mobility (DiagMDS)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Görögország· EU contribution 1 322 640 EUR· until 2030. szept.· 9 countries

• European Commission (Horizon 2020) · ERC-COG

  Identifying spatial determinants of immune cell fate commitment (ImmuNiche)

  Julius-Maximilians-Universitat Wurzburg· Wuerzburg, Németország· EU contribution 1 997 500 EUR· until 2026. dec.

7 of 170 running projects, newest first. Listed amounts together: 121,5 M USD + 3,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Hu8F4 in Treating Patients With Advanced Hematologic Malignancies

  NCT02530034· M.D. Anderson Cancer Center· Frissítve: 2026. nov. 4.

  “FDA Clinical Hold”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

  NCT03150004· Medical College of Wisconsin· Frissítve: 2026. okt. 21.

  “No longer have funding support to complete the pharmacogenetics component.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

  NCT03969446· City of Hope Medical Center· Frissítve: 2026. okt. 20.

  “Accrual goal Met”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  MBG453 in Lower Risk MDS

  NCT04823624· Massachusetts General Hospital· Frissítve: 2026. okt. 20.

  “The trial closed early due to changes in support for the study drug.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

  NCT06454409· City of Hope Medical Center· Frissítve: 2026. okt. 20.

  “resources”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

  NCT06195891· City of Hope Medical Center· Frissítve: 2026. okt. 15.

  “Timeline Adjustment”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

  NCT06630221· Abhay Singh, MD MPH· Frissítve: 2026. okt. 9.

  “Funding unavailable”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Ascorbate in Myelodysplastic Syndrome

  NCT07283900· Prajwal Dhakal· Frissítve: 2026. okt. 9.

  “temporary suspension”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

  NCT06597734· M.D. Anderson Cancer Center· Frissítve: 2026. okt. 5.

  “PI request”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

  NCT06419634· Bristol-Myers Squibb· Frissítve: 2026. okt. 1.

  “Inability to meet protocol objectives”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders

  NCT07683104· National Institute of Allergy and Infectious Diseases (NIAID)· Forrás

• Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

  NCT06303193· National Cancer Institute (NCI)· Forrás

• Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

  NCT05146739· National Cancer Institute (NCI)· Forrás

• BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

  NCT04284787· National Cancer Institute (NCI)· Forrás

• Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

  NCT03953898· National Cancer Institute (NCI)· Forrás

• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

  NCT04802161· National Cancer Institute (NCI)· Forrás

• BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

  NCT04214249· National Cancer Institute (NCI)· Forrás

• Allogeneic iNKT Cell Therapy (agenT-797) After SCT

  NCT07758218· University of Wisconsin, Madison· Forrás

• Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

  NCT04190550· National Cancer Institute (NCI)· Forrás

• ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

  NCT07617363· Washington University School of Medicine· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 3
• CRISPR-Cas Systems 3
• Gene Expression Profiling 12
• Exome Sequencing 8
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 18
• Immunohistochemistry 1
• Liquid Biopsy 1
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 4
• Magnetic Resonance Imaging 8
• Machine Learning 8
• Deep Learning 3
• Cohort Studies 7

• Immunophenotyping of Acute Myeloid Leukemia.

  Methods Mol Biol, 2027. jan.

• Clonal Dynamics of GPI-Deficient Cells in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): A Retrospective Follow-Up Analysis.

  Eur J Haematol, 2026. aug.

• A Robust Computational Workflow Utilizing Generalized Least Squares (GLS) and Generalized Estimating Equations (GEE-GLM) for Longitudinal Flow Cytometry Maturation Data Analysis.

  Cytometry A, 2026. aug.

• Clinical Characteristics and Diagnosis of Myelodysplastic Syndrome Accompanied by Eosinophilia and Basophilia.

  Clin Lab, 2026. aug.

• High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

  Am J Hematol, 2026. júl.

• Evaluation of Neutrophil-Related Parameters by Hematology Analyzer for Detection of Myelodysplastic Syndromes.

  Clin Lab, 2026. júl.

• Diagnostic performance and heterogeneity of validated flow cytometry scores: a systematic review.

  Crit Rev Clin Lab Sci, 2026. ápr.

• Acoustic Imaging Cytometry for High-Throughput Cell Analysis.

  Curr Protoc, 2026. febr.

• Review of flow cytometry findings and associated scoring approaches for identifying myelodysplastic syndrome and the future role of machine learning in improving the diagnostic algorithm.

  Am J Clin Pathol, 2026. jan.

• Acute kidney injury as a harbinger of paroxysmal nocturnal hemoglobinuria in an unsuspected case.

  Indian J Pathol Microbiol, 2026. jan.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.